Considerations for the Terminal Sterilization of Oligonucleotide Drug Products
Nucleic Acid Therapeutics · 01.06.2023 · 33 (3) · 159-177
DOI: 10.1089/nat.2022.0073 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 02.06.2023. Verfasst von Daniel Paul DeCollibus und 13 weiteren Autor:innen. Beteiligte Einrichtung: Drug Product Technology and Engineering, Amgen, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Sterilization, Oligonucleotides, Pharmaceutical Preparations. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A primary function of the parenteral drug product manufacturing process is to ensure sterility of the final product. The two most common methods for sterilizing parenteral drug products are terminal sterilization (TS), whereby the drug product is sterilized in the final container following filling and finish, and membrane sterilization, whereby the product stream is sterilized by membrane filtration and filled into presterilized containers in an aseptic processing environment. Although TS provides greater sterility assurance than membrane sterilization and aseptic processing, not all drug products are amenable to TS processes, which typically involve heat treatment or exposure to ionizing radiation. Oligonucleotides represent an emerging class of therapeutics with great potential for treating a broad range of indications, including previously undruggable targets. Owing to their size, structural complexity, and relative lack of governing regulations, several challenges in drug development are unique to oligonucleotides. This exceptionality justifies a focused assessment of traditional chemistry, manufacturing, and control strategies before their adoption. In this article, we review the current state of sterile oligonucleotide drug product processing, highlight the key aspects to consider when assessing options for product sterilization, and provide recommendations to aid in the successful evaluation and development of TS processes. We also explore current regulatory expectations and provide our interpretation as it pertains to oligonucleotide drug products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Product Technology and Engineering, Amgen, Cambridge, Massachusetts, USA.
- Pharmaceutical Development, Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
- CVRM CMC Projects, Pharmaceutical Sciences, AstraZeneca R&D, Gothenburg, Sweden.
- New Modalities and Parenteral Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, United Kingdom.
- Global Drug Development, Technical Research & Development, Novartis Pharma AG, Basel, Switzerland.
- GSK, Strategic External Development, Analytical Development, Collegeville, Pennsylvania, USA.
Zitieren
APA
DeCollibus, D. P., Searcy, J., Tivesten, A., Akhtar, N., Lindenberg, C., Abarrou, N., Pradhan, S., Fiandaca, M., Franklin, J., Govindan, G., Liu, H. Y., Royle, D., Soo, P. L., & Storch, K. (2023). Considerations for the Terminal Sterilization of Oligonucleotide Drug Products. Nucleic Acid Therapeutics, 33(3), 159-177. https://doi.org/10.1089/nat.2022.0073
Vancouver
DeCollibus DP, Searcy J, Tivesten A, Akhtar N, Lindenberg C, Abarrou N, et al. Considerations for the Terminal Sterilization of Oligonucleotide Drug Products. Nucleic Acid Therapeutics. 2023;33(3):159-177. doi:10.1089/nat.2022.0073
BibTeX
@article{DeCollibus2023,
author = {DeCollibus, Daniel Paul and Searcy, Justin and Tivesten, Anna and Akhtar, Nadim and Lindenberg, Christian and Abarrou, Nounja and Pradhan, Sujana and Fiandaca, Maggie and Franklin, Jenny and Govindan, Geetha and Liu, Hung-Yi and Royle, David and Soo, Patrick Lim and Storch, Kirsten},
title = {Considerations for the Terminal Sterilization of Oligonucleotide Drug Products},
journal = {Nucleic Acid Therapeutics},
year = {2023},
volume = {33},
number = {3},
pages = {159--177},
doi = {10.1089/nat.2022.0073}
}
EUVIMED